Month: July 2018

New hATTR Treatments Under Review for their ‘Value for Money’
Two vitally important reviews are underway for patisiran and inotersen, new treatments that have been trialed for hATTR patients. One review is led by the National Institute for Health and Clinical Excellence (NICE) in the UK. (more…)
Read More
ARC CEO Named Representative of Patient Engagement Collaborative
To strengthen patient involvement, the U.S. Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced the launch of the Patient Engagement Collaborative (PEC). (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
22 (G1) FORTH STREET, EDINBURGH, UK EH1 3LH | +44 (0) 131 550 3866
arc@arci.org

ARC is a 501(c)(3) nonprofit organization